La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?

• Ce qui fait monter. Company’s public moves suggest confidence in an imminent hypertension approval (Endpoints News, tier 2)
• Ce qui fait monter. NDA acceptance and a set PDUFA target date indicate FDA is proceeding toward a decision (hand‑verified tier 1)
• Ce qui fait descendre. Recent Phase 2 OSA trial failed, raising possible safety/efficacy concerns for the same molecule (hand‑verified tier 1)
• Ce qui fait descendre. Base‑rate for new‑mechanism drugs is only 64%, reflecting inherent uncertainty
• Ce qui ferait le plus bouger ce chiffre. The FDA’s final decision at the PDUFA date – whether it issues approval or a complete response letter.

• Ce qui fait monter. NDA acceptance and scheduled PDUFA date indicate a review will occur, raising the likelihood of approval. [1]
• Ce qui fait descendre. No tier 1 or 2 evidence of approval or positive data for hypertension, and the mechanism is new with no prior approvals, lowering confidence. [4]
• Ce qui ferait le plus bouger ce chiffre. Whether the FDA will find the efficacy and safety data sufficient for approval; a rejection would drop the probability dramatically.

• Ce qui fait monter. NDA acceptance and a PDUFA target date of 22 Dec 2026 indicate the FDA has moved the application forward (tier 2).
• Ce qui fait descendre. No hypertension efficacy data or safety signals have been reported; the mechanism is novel and has no prior approvals, lowering confidence in a favorable outcome (tier 2).
• Ce qui ferait le plus bouger ce chiffre. The availability and quality of hypertension trial data and the safety profile of lorundrostat will most influence the approval likelihood.

• Ce qui fait monter. NDA acceptance and PDUFA target date of 22 Dec 2026 indicate the agency has reviewed the data and is proceeding to decision (tier 2).
• Ce qui fait descendre. No published data on hypertension efficacy or safety; the mechanism is novel with no prior approvals for this indication, raising uncertainty (tier 2).
• Ce qui ferait le plus bouger ce chiffre. The actual clinical and safety data for hypertension will most influence the outcome.

• Ce qui fait monter. The FDA accepted the NDA for lorundrostat with a target PDUFA action date of December 22, 2026, supported by positive Phase 3 clinical trial data in hypertension [tier 2].
• Ce qui fait monter. Mineralys Therapeutics has undertaken major financial and operational preparations ahead of the target action date, indicating strong readiness for launch [tier 2].
• Ce qui fait descendre. As an aldosterone synthase inhibitor, lorundrostat represents a novel mechanism of action not previously approved in the US for hypertension, introducing higher regulatory scrutiny [tier 1].
• Ce qui fait descendre. First-cycle approvals remain subject to manufacturing (CMC) or unexpected regulatory hurdles that frequently trigger Complete Response Letters [tier 3].
• Ce qui ferait le plus bouger ce chiffre. Whether any unforeseen manufacturing (CMC) issues or late-stage FDA requests delay the review or result in a Complete Response Letter before December 22, 2026.

• Ce qui fait monter. Positive Phase 3 Launch-HT data reported in March 2026 supports the efficacy of lorundrostat for hypertension [2, 5].
• Ce qui fait monter. AstraZeneca's May 2026 approval in the hypertension space validates the therapeutic landscape and potentially the aldosterone synthase inhibitor class [2, 4].
• Ce qui fait monter. Mineralys' $200M expenditure to eliminate future royalties on lorundrostat indicates high internal confidence in the drug's approval and commercial success [4, 9].
• Ce qui fait monter. The company is actively preparing for a commercial launch, as evidenced by its participation in major investor conferences [4, 6].
• Ce qui fait descendre. The resolution criterion is strict: any PDUFA extension or Complete Response Letter (CRL) results in a 'No' [Resolution].
• Ce qui fait descendre. There is a significant historical risk of CRLs due to non-clinical factors such as manufacturing (over 50%) or product quality (41%) [3, 11].
• Ce qui fait descendre. Lorundrostat failed a related Phase 2 trial in obstructive sleep apnea, which may indicate limitations in its broader clinical profile [1].
• Ce qui ferait le plus bouger ce chiffre. The primary uncertainty is the risk of a PDUFA date extension or a CRL due to manufacturing or quality issues, which are common causes for first-cycle failures even when clinical data is strong.

Raisons non conservées pour cette révision (l'historique détaillé n'est gardé que depuis peu).

Raisons non conservées pour cette révision (l'historique détaillé n'est gardé que depuis peu).